A Placebo-Controlled Pilot Study of the Ampakine CX516 Added to Clozapine in Schizophrenia
Autor: | Lawrence Herz, Andrew C. Leon, Ileana Berman, Leslie Leahy, Gary Lynch, Steven A. Johnson, Donald C. Goff, Thomas Posever |
---|---|
Rok vydání: | 2001 |
Předmět: |
Adult
Male Ampakine Psychosis medicine.drug_class Pilot Projects Dioxoles Placebo law.invention Cognition Double-Blind Method Piperidines Randomized controlled trial Memory law medicine Humans Attention Pharmacology (medical) Clozapine Psychological Tests Dose-Response Relationship Drug Memoria Middle Aged CX-516 medicine.disease Psychiatry and Mental health Schizophrenia Anesthesia Drug Therapy Combination Female Psychology Antipsychotic Agents medicine.drug |
Zdroj: | Journal of Clinical Psychopharmacology. 21:484-487 |
ISSN: | 0271-0749 |
DOI: | 10.1097/00004714-200110000-00005 |
Popis: | CX516, a positive modulator of the glutamatergic alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor, improves performance in tasks requiring learning and memory in animals. CX516 was added to clozapine in 4-week, placebo-controlled, dose-finding (N = 6) and fixed-dose (N = 13) trials. CX516 was tolerated well and was associated with moderate to large, between-group effect sizes compared with placebo, representing improvement in measures of attention and memory. These preliminary results suggest that CX516 and other "ampakines" hold promise for the treatment of schizophrenia. |
Databáze: | OpenAIRE |
Externí odkaz: |